Public health groups raise concern on patent grant to promising, new HIV drug Patient and public health groups have raised concerns over a potential patent grant to Gilead Sciences for the HIV drug ...

PURPOSE ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Ending Acquired Immune Deficiency Syndrome (AIDS) as a public health threat here by 2030 will take much effort as it will all around the world. The key, ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

The fund invests more than S$6.4 billion a year to fight tuberculosis, malaria, and HIV. Read more at straitstimes.com.

The ministry of Health has announced the administration of the first dose of Cabotegravir (Cab-LA) as part of Uganda’s ...

Peter Sands, head of the Global Fund, warned that climate change and conflict could undermine health improvements. Despite progress, funding concerns persist for 2026-2028 efforts. The 2024 report ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

吉利德艾滋病预防药物再次交出积极结果吉利德科学周四披露的结果显示，艾滋病毒暴露前预防（PrEP）新药来那卡帕韦（lenacapavir）再次展现出了极高的有效性。在lenacapavir组2180名受试者中，只有2例新发病例，99.9%的参与者没有感染HIV，相对风险降低96%；对照组1087名受试者中有9例新发病例。截至周四收盘，吉利德科学收涨2.74%，迫近历史高位。 艾滋病龙头吉利德股价逼近 ...